Literature DB >> 28057672

Targeting CD19: the good, the bad, and CD81.

Mireya Paulina Velasquez1, Stephen Gottschalk1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28057672      PMCID： PMC5216268          DOI： 10.1182/blood-2016-11-749143

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.

Authors:  Rebecca Gardner; David Wu; Sindhu Cherian; Min Fang; Laïla-Aïcha Hanafi; Olivia Finney; Hannah Smithers; Michael C Jensen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

2.  Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.

Authors:  Hui Yu; Elena Sotillo; Colleen Harrington; Gerald Wertheim; Michele Paessler; Shannon L Maude; Susan R Rheingold; Stephan A Grupp; Andrei Thomas-Tikhonenko; Vinodh Pillai
Journal:  Am J Hematol       Date:  2016-11-21       Impact factor: 10.047

3.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

Review 4.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.

Authors:  Jae H Park; Mark B Geyer; Renier J Brentjens
Journal:  Blood       Date:  2016-05-20       Impact factor: 22.113

5.  CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency.

Authors:  Menno C van Zelm; Julie Smet; Brigitte Adams; Françoise Mascart; Liliane Schandené; Françoise Janssen; Alina Ferster; Chiung-Chi Kuo; Shoshana Levy; Jacques J M van Dongen; Mirjam van der Burg
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

Review 6.  Blinatumomab: A novel, bispecific, T-cell engaging antibody.

Authors:  Megan Brafford May; Ashley Glode
Journal:  Am J Health Syst Pharm       Date:  2016-01-01       Impact factor: 2.637

7.  Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.

Authors:  Friederike Braig; Anna Brandt; Mariele Goebeler; Hans-Peter Tony; Anna-Katharina Kurze; Peter Nollau; Thomas Bumm; Sebastian Böttcher; Ralf C Bargou; Mascha Binder
Journal:  Blood       Date:  2016-10-26       Impact factor: 22.113

Review 8.  Function of the tetraspanin molecule CD81 in B and T cells.

Authors:  Shoshana Levy
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

9.  Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.

Authors:  Catherine M Bollard; Stephen Gottschalk; Vicky Torrano; Oumar Diouf; Stephanie Ku; Yasmin Hazrat; George Carrum; Carlos Ramos; Luis Fayad; Elizabeth J Shpall; Barbara Pro; Hao Liu; Meng-Fen Wu; Daniel Lee; Andrea M Sheehan; Youli Zu; Adrian P Gee; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544
  9 in total
  4 in total

1.  Open conformation of tetraspanins shapes interaction partner networks on cell membranes.

Authors:  Yihu Yang; Xiaoran Roger Liu; Zev J Greenberg; Fengbo Zhou; Peng He; Lingling Fan; Shixuan Liu; Guomin Shen; Takeshi Egawa; Michael L Gross; Laura G Schuettpelz; Weikai Li
Journal:  EMBO J       Date:  2020-08-16       Impact factor: 11.598

2.  Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells.

Authors:  Gang Xue; Ningbo Zheng; Jing Fang; Guangxu Jin; Xiaoyin Li; Gianpietro Dotti; Qing Yi; Yong Lu
Journal:  Cancer Cell       Date:  2021-10-21       Impact factor: 31.743

3.  Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.

Authors:  Seyed Reza Banihashemi; Ahmad Zavaran Hosseini; Fatemeh Rahbarizadeh; Davoud Ahmadvand
Journal:  Iran J Basic Med Sci       Date:  2018-05       Impact factor: 2.699

4.  Blinatumomab in Ph+ B-ALL: present and perspectives.

Authors:  Cristina Papayannidis; Giovanni Martinelli
Journal:  Oncotarget       Date:  2017-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.